Yao-Yu Wu, MD

Articles by Yao-Yu Wu, MD

Although surgery and radiotherapy are standard treatments for localized STS, the role of adjuvant chemotherapy, particularly doxorubicin, in high-grade STS is debated.

Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study

ByShiny Chih-Hsuan Wu, MD,Yao-Yu Wu, MD,Chi-Ting Liau, MD,Chih‑Hsiang Chang, MD,Shih-Chiang Huang, MD,Hsin‑Nung Shih, MD,Chun-Chieh Chen, MD, PhD

March 26th 2026

Latest Updated Articles

Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study
March 26th 2026

Trending on CancerNetwork

177Lu-Edoterotide Handed CRL by FDA For GEP-NETs Treatment

DESTINY Trials May Reshape HER2-Positive Breast Cancer Care With T-DXd

BI-1808 Earns FDA Fast Track Status for Advanced Ovarian Cancer

How Is City of Hope Widening National Clinical Trial Access for Oncology?

Bispecific Antibodies for Older Patients With Relapsed/Refractory Multiple Myeloma